The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Update on the ICARIA-MM trial
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the latest data from a number of Phase III trials investigating the use of isatuximab, a CD38-targeting monoclonal antibody, combined with immunomodulatory/proteasome-targeting agents for the treatment of relapsed/refractory (R/R) multiple myeloma. Dr Richardson shares updated data from the Phase III ICARIA-MM trial (NCT02990338), currently investigating the use of isatuximab plus pomalidomide and low-dose dexamethasone compared to pomalidomide and low-dose dexamethasone in R/R multiple myeloma. The trial demonstrated significantly improved outcomes for patients treated with isatuximab plus pomalidomide and low-dose dexamethasone, with a median progression-free survival of 17.5 months compared to 13 months. Dr Richardson also speaks on the longer-term outcomes such as overall survival (OS) and time to next treatment (TTNT), suggesting a favorable efficacy profile for its use in the R/R domain. Dr Richardson compares this data with results from the Phase III APOLLO trial (NCT03180736), demonstrating similar efficacy patterns. Additionally, Dr Richardson shares data from the Phase III IKEMA trial (NCT03275285) which is investigating the combination of isatuximab plus carfilzomib and dexamethasone, again achieving significant PFS. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Paul Richardson, MD, has received institutional research support from Oncopeptides, Celgene/BMS, Takeda, and Karyopharm. He has received honoraria for his role as an Advisory Committee member from Karyopharm, Oncopeptides, Celgene/BMS, Takeda, Janssen, Sanofi, Secura Bio, GSK, Regeneron, AstraZeneca, and Protocol Intelligence.
